Drugs / JNJ-81201887
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05811351 | Mar 2023 → Feb 2026 | diffuse secondary choroid atrophy | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06635148 Background | Sep 2024 → Aug 2029 expected | diffuse secondary choroid atrophy, macular degeneration | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-81201887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635148 ↗ |
| Known as | AAVCAGsCD59 | “JNJ-81201887 (AAVCAGsCD59)” NCT06635148 ↗1“AAVCAGsCD59” NCT05811351 ↗ |
| Route | Intravitreal | “JNJ-81201887 will be administered as intravitreal injection.” NCT05811351 ↗ |